GlassScriptPhysician profile
Jeremiah D Coffey
NPI 1427353200
$455.16
in general payments reported to CMS, 2019-2025
12 companies · $185 in 2025
The $185 reported for 2025 was more than what 87% of Chiropractor providers received nationally (typical 2025 total: $40.91).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $36.94 · 2023: $70.94 · 2024: $26.09 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $167.86 | 2023-2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $61.61 | 2025 | |
| Amgen INC. | $47.04 | 2019 | |
| Tersera Therapeutics LLC | $31.34 | 2019 | |
| Abbvie INC. | $30.14 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $22.27 | 2023 | Zilretta, Iovera |
| Grt US Holding, INC. | $20.70 | 2021 | |
| Boston Scientific Corporation | $16.31 | 2019 | |
| Pacira Therapeutics, INC. | $16.25 | 2019 | |
| Almatica Pharma LLC | $16.24 | 2021 | |
| Bioventus LLC | $13.84 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremiah Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.